Brian Fuehrlein, MD, PhD
Associate Professor of PsychiatryCards
About
Research
Publications
2025
Study protocol of a hybrid type 1 effectiveness-implementation multisite trial: Dialectical behavior therapy skills group for Veterans at high-risk for suicide attempt
Decker S, Kroll-Desrosiers A, Mattocks K, Aunon F, Galliford E, DeRycke E, Doran N, Baird S, Rielage J, Ridley J, Bannister J, Giovannelli T, Fuehrlein B, Shriver C, Spana E, Honsberger M, Demirelli S, Shest E, Landes S, Goodman M, Martino S. Study protocol of a hybrid type 1 effectiveness-implementation multisite trial: Dialectical behavior therapy skills group for Veterans at high-risk for suicide attempt. Contemporary Clinical Trials 2025, 151: 107828. PMID: 39923893, DOI: 10.1016/j.cct.2025.107828.Peer-Reviewed Original ResearchConceptsDialectical behavior therapyTreatment-as-usualDialectical Behaviour Therapy Skills GroupSuicide attemptsEmotion dysregulationComponents of dialectical behavior therapyComprehensive DBTVeterans Health AdministrationTherapist consultation teamSkill groupsNon-veteran samplesReduce suicide attemptsAdjunctive treatmentSelf-directed violenceBehavioral therapySuicidal behaviorSuicideMultisite trialEffectiveness trialHigh-risk veteransVeteransPost-randomizationSuicide deathsEmotionsRandomized controlled trialsIn Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder.
Sharafshah A, Lewandrowski K, Gold M, Fuehrlein B, Ashford J, Thanos P, Wang G, Hanna C, Cadet J, Gardner E, Khalsa J, Braverman E, Baron D, Elman I, Dennen C, Bowirrat A, Pinhasov A, Modestino E, Carney P, Cortese R, Fiorelli R, Schmidt S, Pollack A, Badgaiyan R, Blum K. In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder. Current Neuropharmacology 2025, 23 PMID: 39865816, DOI: 10.2174/011570159x349579241231080602.Peer-Reviewed Original ResearchGenetic Addiction Risk ScoreSubstance use disordersReward Deficiency SyndromeAlcohol use disorderSuicidal ideationDepressive phenotypeGlucagon-like peptide-1Use disorderAnti-addictive compoundsGLP1R agonistsAntiaddictive effectsDopamine signalingDopaminergic signalingGlucagon-like peptide-1 agonistsRisk scoreDopamine regulationDopamine homeostasisGlucagon-like peptide-1 receptorEmpirical clinical studiesPeptide-1 receptorIdeationDeficiency syndromeDisordersLong-term inductionTherapeutic advantageTime to Admit Genes and Epigenetics are Indeed the Blueprint for a Rewardful Life Whereby the Organism Controls the Genome
Blum K, Braverman E, Lewandowski K, Gold M, Gardner E, Elman I, OscarBerman M, Cadet J, Sharafshah A, A Dennen C, Bowirrat A, Pinhasov A, Baron D, Levin C, Gondre-Lewis M, Badgaiyan R, Khalsa J, Sunder K, Murphy K, Makale M, Modestino E, Jafari N, Zeine F, PL Lewandrowski A, A Madigan M, Fuehrlein B, K Thanos P. Time to Admit Genes and Epigenetics are Indeed the Blueprint for a Rewardful Life Whereby the Organism Controls the Genome. Acta Scientific Neurology 2025, 03-09. DOI: 10.31080/asne.2025.08.0794.Peer-Reviewed Original Research
2024
Harm Reduction Treatment for Substance Use
by: R, Fuehrlein B. Harm Reduction Treatment for Substance Use. Journal Of Psychiatric Practice 2024, 30: 385-385. DOI: 10.1097/pra.0000000000000805.Peer-Reviewed Original ResearchA detox dilemma beyond benzodiazepines; clonidine's quandary in alcohol withdrawal management
Johnson M, Cosentino D, Fuehrlein B. A detox dilemma beyond benzodiazepines; clonidine's quandary in alcohol withdrawal management. American Journal On Addictions 2024, 34: 101-103. PMID: 39096168, DOI: 10.1111/ajad.13640.Peer-Reviewed Original ResearchPsychiatric emergency roomAlcohol withdrawalBenzodiazepine useAmerican Society of Addiction Medicine guidelinesTreatment of alcohol withdrawalClinical Institute Withdrawal AssessmentAWS managementAlternative agentsComorbid hypertensionEmergency roomVeterans AffairsRetrospective chart reviewWithdrawal AssessmentOpioid withdrawalBenzodiazepine doseAdjunctive medicationsAlcohol withdrawal managementBenzodiazepinesWithdrawal managementDepartment of Veterans AffairsVeteran populationClonidine useMedication dosesChart reviewSyndromic managementSolving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy.
Zeine F, Jafari N, Baron D, Bowirrat A, Pinhasov A, Norling B, Martinez K, Nami M, Manavi N, Sunder K, Rabin D, Bagchi D, Khalsa J, Gold M, Sipple D, Barzegar M, Bodhanapati J, Khader W, Carney P, Dennen C, Gupta A, Elman I, Badgaiyan R, Modestino E, Thanos P, Hanna C, McLaughlin T, Cadet J, Soni D, Braverman E, Barh D, Giordano J, Edwards D, Ashford J, Gondre-Lewis M, Gilley E, Murphy K, Lewandrowski K, Sharafshah A, Makale M, Fuehrlein B, Blum K. Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy. Journal Of Neuroimaging In Psychiatry And Neurology 2024, 8: 50-95. PMID: 39635461, PMCID: PMC11615735.Peer-Reviewed Original ResearchCenters for Disease Control and PreventionSubstance use disordersOpioid crisisOpioid substitution therapyGenetic Addiction Risk SeveritySubstance Abuse and Mental Health Services AdministrationIntegrative therapiesMental Health Services AdministrationDisease Control and PreventionHealth Services AdministrationControl and PreventionIllicit drug useWeb of Science databasesServices AdministrationComprehensive treatment approachHarm reductionDopamine homeostasisSystematic reviewNational surveyRelevant articlesBrain Reward CascadeMortality tollOverdose deathsGoogle ScholarProvisional figuresA Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Celik M, Gold M, Fuehrlein B. A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. Brain Sciences 2024, 14: 294. PMID: 38539681, PMCID: PMC10969323, DOI: 10.3390/brainsci14030294.Peer-Reviewed Original ResearchAlcohol use disorderUse disorderTreatment of alcohol use disordersGLP-1 receptor agonistsCurrent treatment landscapeAlcohol withdrawal syndromePhosphodiesterase-4 inhibitorWithdrawal syndromeTreatment landscapeReceptor agonistsTreatment modalitiesGlobal disease burdenPhosphodiesterase-4GLP-1Disease burdenNarrative reviewDisordersAnnual deathsMedicationTreatmentAlcoholPsychotherapyPsychedelicsHealth conditionsOpioid use disorder: current trends and potential treatments
Lee Y, Gold M, Blum K, Thanos P, Hanna C, Fuehrlein B. Opioid use disorder: current trends and potential treatments. Frontiers In Public Health 2024, 11: 1274719. PMID: 38332941, PMCID: PMC10850316, DOI: 10.3389/fpubh.2023.1274719.Peer-Reviewed Original ResearchConceptsOpioid use disorderNovel approaches to treatmentTreatment of opioid use disorderComorbid disordersRemitting disorderApproach to treatmentMedication treatment of opioid use disorderUse disorderSubstance useInterventional treatmentPublic health threatFDA approvalTreatment approachesBuprenorphine prescribingHarm reduction strategiesMedical treatmentMedical conditionsDisordersOverdoseLess stigmaTreatmentOverdose deathsElectromagnetic therapyDeathReduce overdosesAnalysis of nonfatal suicide attempts and demographic characteristics of US military veterans with opioid use disorder: A descriptive VA medical center study
Celik M, Cosentino D, Fuehrlein B. Analysis of nonfatal suicide attempts and demographic characteristics of US military veterans with opioid use disorder: A descriptive VA medical center study. American Journal On Addictions 2024, 33: 347-350. PMID: 38273434, DOI: 10.1111/ajad.13519.Peer-Reviewed Original ResearchPrevalence of comorbid psychiatric conditionsVA Medical CenterCohort of veteransSuicide attemptsUS military veteransTreat OUDNonfatal suicide attemptsOpioid use disorderLifetime suicide attempt ratePrevent suicideHousing instabilityMilitary veteransVeteransDemographic characteristicsComorbid psychiatric conditionsLifetime suicide attemptsOUD diagnosisMedical CenterSuicide attempt rateHigh riskUse disorderPsychiatric conditionsPatient populationAttempt rateOUD
2023
US Medicaid program: An analysis of the spending and utilization patterns for antidepressants from 2017 to 2021
Elmarasi M, Fuehrlein B. US Medicaid program: An analysis of the spending and utilization patterns for antidepressants from 2017 to 2021. Exploratory Research In Clinical And Social Pharmacy 2023, 13: 100392. PMID: 38149102, PMCID: PMC10750172, DOI: 10.1016/j.rcsop.2023.100392.Peer-Reviewed Original ResearchMajor depressive disorderMonoamine oxidase inhibitorsTricyclic antidepressantsDepressive disorderCommon mental health concernsStudy periodClasses of antidepressantsMedicaid programUS Medicaid programMental health conditionsSerious mental health conditionsPublic health systemMental health concernsAntidepressant prescriptionsSingle antidepressantTreatment patternsAntidepressant usagePrescription dataMedicaid dataUS adultsAntidepressantsHealth complicationsLifetime diagnosisOxidase inhibitorsHealth system
Academic Achievements & Community Involvement
News
News
- December 12, 2024
Fuehrlein, Pérez Palmer, Wilkins Promoted at VA
- August 27, 2024Source: Psychology Today
Smoking Hard Drugs Is Now Killing Many Users
- April 02, 2024
Fuehrlein Appointed Chief Mental Health Consultant at VA Central Office
- February 28, 2024Source: Psychology Today
Ask the Expert: An Interview With Yale's Brian Fuehrlein, MD, PhD
Get In Touch
Contacts
Mailing Address
Psychiatry
VA Connecticut Healthcare System, 950 Campbell Ave
West Haven, CT 06516
United States